GI Effects IG
GI Effects IG
GI Effects IG
2008 Metametrix, inc. All rights reserved GI Effects Stool Profiles U.S. patent pending 70040 rev 0708 v2
Predominant Bacteria
Microorganisms in the GI tract perform a host of useful functions, such as fermenting unused energy substances, communicating with the immune system, preventing growth of harmful species, regulating the development of the gut, producing vitamins for the host (such as biotin and vitamin K), and producing hormones to direct the host to store fats.[1] Intestinal microflora are also thought to have many beneficial local and systemic roles such as improving lactose tolerance, supplying short chain fatty acids (SCFA) as an energy substrate for the host, anti-tumor properties, neutralizing certain toxins, stimulating the intestinal immune system, reducing blood lipid levels and preventing obesity and type II diabetes.[2] Under normal homeostatic conditions, the intestinal microflora are of central importance in preventing colonization by pathogens, termed colonization resistance.[3] Predominant organisms are considered to be beneficial when they are in balance.
Opportunistic Bacteria
Opportunistic Bacteria present
Significance:
Generally self-limiting and not normally considered pathogenic Often exacerbated by low predominant bacteria, pathogen or parasite infection, poor diet, antibiotic use, and lowered gut immunity.
Treatment Options:
Probiotics Prebiotics: Do not use fructooligosaccharide (FOS) if Klebsiella sp. or Citrobacter sp. are present. May need to use anti-microbial agents followed by preand probiotics Herbal agents include goldenseal, citrus seed extract, garlic, uva ursi, oregano oil, and olive leaf extract Visit www.emedicine.com to search for the pathology of the individual opportunistic bacteria and treatment options. Address other GI Effects abnormalities
Treatment Options:
Probiotics Prebiotics such as psyllium, oat bran, oligofructose, xylooligosaccharide, inulin, beta-glucan, and/or arabinogalactan[6] Increase intake of fresh vegetables and fibers Address other GI Effects abnormalities
Pathogenic Bacteria
Pathogenic Bacteria present Helicobacter pylori
Helicobacter pylori (H. pylori) bacterium causes peptic ulcer disease and has been associated with increased gastric cancer risk. H. pylori is a Type I carcinogen. It is estimated that 50% of the worlds population is infected with H. pylori.
Symptoms:
Acute gastritis with abdominal pain, nausea and vomiting, usually within two weeks of infection. Recurrent abdominal symptoms (non-ulcer dyspepsia) without ulcer disease are common.
Treatment Options:
Reduce poor quality fats, refined carbohydrates and sugars, and encourage intake of fresh vegetables. High fiber foods might exacerbate patient symptoms. For Lactobacillus sp. or Clostridia sp. overgrowth, supplement with Bifidobacter sp. or Saccharomyces boulardii probiotics, respectively. May need to use anti-microbial agents Address other GI Effects abnormalities Balance flora using appropriate probiotics
Symptoms:
Cramping, lower abdominal pain, fever and diarrhea usually decreases once antibiotics are stopped, though can continue for up to 4 weeks
Yeast/Fungi
Yeast/Fungi present
Commonly identified species: Candida, Rhodotorula, Geotrichum, Sacchoromyces, Trichosporon, Candida are detailed below. If other commonly identified species are reported, consider patient symptoms and degree of infection to decide if anti-fungal therapy is warranted. Saccharomyces sp. may be reported if patient is supplementing with S. boulardii. Restore proper predominant microflora populations and address all other imbalances found on the GI Effects test report.
Campylobacter sp.
Contaminated animal food sources are the primary cause, especially poultry and red meat. Dogs may also become infected from rodents and birds and infect humans. Suspect hydrochloric acid insufficiency and/or secretory IgA deficiency.
Candida sp.
Candida sp. is a normal inhabitant of the gastrointestinal flora and is present in 40-65% of the human population with no harmful effects. However, in conditions allowing for overgrowth, Candida sp. is the most common causal agent of opportunistic fungal infections. The esophagus is the most commonly infected site, followed by the stomach then the small and large bowel. Approximately 15% of people develop systemic candidiasis.
Symptoms:
Symptom onset is generally abrupt. Influenza-like symptoms are common, including headache and malaise. GI symptoms include abdominal pain, nausea, and vomiting. The degree of diarrhea varies. Campylobacter sp. has been associated with reactive arthritis.
Symptoms:
Gastric pain, nausea and vomiting, gas, bloating, intestinal permeability, imbalance in gut microflora, opportunistic bacterial infection
Treatment Options:
Reduce intake of refined carbohydrates and sugars Prescriptive agents: fluconazole, intraconazole, ketoconazole, nystatin Herbal agents (use in combination for greater efficacy): oregano oil, berberine, goldenseal, undecylenic acid, caprylic acid, grapefruit seed extract, uva ursi, garlic (allicin) S. boulardii aids in the growth of beneficial bacteria, crowds out yeast, and helps with immune support Avoid fructooligosaccharide (FOS) as it may feed the yeast
Symptoms:
Typical symptoms include severe abdominal cramping, watery or bloody diarrhea, and vomiting. In some cases (up to 10%) it can cause hemorrhagic colitis or hemolytic uremic syndrome.
Treatment Options:
The infection is generally self-limiting Rehydrate if diarrhea is present
Yeast/Fungi Parasites
Treatment Options:
Reduce intake of refined carbohydrates and sugars If presentation is consistent with a fungal infection, use antifungals followed by prebiotics and probiotics Avoid FOS powder as it may feed the yeast Address other abnormal results on the GI Effects test first, with the expectation that rare yeast/fungi will be crowded out when healthy conditions are restored
Treatment Options:
Praziquantel, 75 mg/kg/d PO in 3 doses x 2d Albendazole 10 mg/kg/d PO x 7d Botanicals* (see page 7)
Cryptosporidium
Water, including swimming pools, is a common source of contamination as it is resistant to chlorine. Outbreaks are associated with raw milk and meat, and Cryptosporidium is a likely cause of travelers diarrhea.
Parasites
Parasite present
Pharmaceutical recommendations for each parasite are from the 2007 publication in The Medical Letter, Drugs for Parasitic Infections.[14]
Symptoms:
Watery diarrhea is the most frequent symptom, and can be accompanied by dehydration, weight loss, abdominal pain, fever, nausea and vomiting. May be very severe in immunocompromised patients.
Blastocystis sp.
Blastocystis sp. is transmitted via fecal-oral route or from contaminated food or water. Seven subspecies have been identified and Blastocystis sp. 4 infection has been correlated with disease. Blastocystis sp. 2 is considered to be asymptomatic.[15-17]
Treatment Options:
Usually self-limiting in an immunocompetent person, with symptoms lasting 1-2 weeks If symptoms persist look for possible water contamination Nitazoxanide, 500 mg PO bid x 3d for persistent infections Botanicals* (see page 7)
Symptoms:
May include diarrhea, cramps, nausea, fever, vomiting, abdominal pain or fatigue. Blastocystis sp. has been associated with irritable bowel syndrome, infective arthritis and intestinal obstruction. In certain cases, chronic fatigue may be the only complaint.
Dientamoeba fragilis
Fecal-oral transmission and water contamination are common sources. Often accompanies pinworm.
Treatment Options:
Blastocystis sp. can be prevented by personal hygiene and sanitary conditions Clinical significance of infection by these organisms is controversial Metronidazole 750 mg PO tid x 10d or iodoquinol 650 mg PO tid x 20d or trimethoprim/sulfamethoxazole 1 DS tab PO bid x 7d have been reported to be effective Infection is difficult to get rid of, botanicals may not be strong enough. Use of broad spectrum antiparasitic botanicals is most effective.* Botanicals* (see page 7)
Symptoms:
Diarrhea, fatigue and abdominal bloating, although often asymptomatic. In chronic infections, abdominal tenderness, nausea and weight loss may be present.
Treatment Options:
Iodoquinol, 650 mg PO tid x 20d; Paromomycin, 25-35 mg/kg/d PO in 3 doses x 7d; Tetracycline, 500 mg PO qid x 10d or Metronidazole, 500-750 mg PO tid x 10d Botanicals* (see page 7)
Symptoms :
Frequently asymptomatic. Inflammation and intermittent obstruction of the biliary ducts. Acute abdominal pain, nausea, diarrhea and eosinophilia can occur. In long-standing infections, cholangitis, cholelithiasis, pancreatitis and cholangiocarcinoma can develop.
Parasites
Entamoeba histolytica
Entamoeba histolytica is the only amoeba considered pathogenic. Contaminated food or water, pets, sexual contact, and fecal-oral route are possible sources of transmission. Cysts are sensitive to chlorinated water.
Symptoms:
Often asymptomatic. Incubation period is 1-3 weeks and symptoms range from acute diarrhea, to chronic diarrhea with bloating, intestinal malabsorption, steatorrhea (possibly due to bile salt deconjugation) and weight loss. Generally self-limiting, however 30-60% develop chronic giardiasis. Unusual presentations include allergic manifestations such as urticaria, reactive arthritis, and biliary tract disease. May induce lactose intolerance, B12 deficiency and reduced sIgA.
Symptoms:
Range from asymptomatic to fulminating colitis (resembling ulcerative colitis), dysentery, and extraintestinal lesions on the liver, lung, brain, skin and other tissues
Treatment Options:
Asymptomatic carriers should be treated in order to avoid spread For asymptomatic patients: Iodoquinol, 650 mg PO tid x 20d; Paromomycin, 25-35 mg/kg/d PO in 3 doses x 7d or Diloxanide furoate, 500 mg PO tid x 10d For mild to moderate intestinal disease: Metronidazole, 500-750 mg PO tid x 7-10d or Tinidazole, 2 g once PO daily x 3d followed by either Iodoquinol, 650 mg PO tid x 20d or Paromomycin, 25-35 mg/kg/d PO in 3 doses x 7d For severe intestinal and extraintestinal disease: Metronidazole, 750 mg PO tid x 7-10d or Tinidazole, 2 g once PO daily x 5d followed by either Iodoquinol, 650 mg PO tid x 20d or Paromomycin, 25-35 mg/kg/d PO in 3 doses x 7d Botanicals* (see page 7)
Treatment Options:
Metronidazole 250 mg PO tid x 5-7d Avoid fatty foods as giardia feeds on bile salts Paromomycin, 25-35 mg/kg/d PO in 3 doses x 5-10d; or Furazolidone, 100 mg PO qid x 7-10d; or Quinacrine, 100 mg PO tid x 5d Botanicals* (see page 7)
Symptoms:
Itching and a rash at the site of penetration. While a light infection may cause no symptoms, heavy infection can cause anemia, abdominal pain, diarrhea, loss of appetite and weight loss. Has been associated with reactive arthritis.
Treatment Options:
Albendazole, 400 mg PO once; Mebendazole, 100 mg PO bid x 3d or 500 mg once, or Pyrantel pamoate, 11 mg/kg (max. 1g) PO x 3d Botanicals* (see page 7)
Symptoms:
Nocturnal perianal pruritus which can lead to skin bacterial infection, abdominal pain and anorexia. It may enter the vagina and has been associated with some cases of cystitis.
Schistosoma mansoni
Schistosoma mansoni is transmitted through skin contact with contaminated water or oral ingestion. Larvae can migrate to the lungs and liver and can live for 25-30 years. Eggs secrete an enzymatic substance that destroys surrounding tissues.
Treatment Options:
Mebendazole, 100 mg PO once, repeat in 2 weeks; Pyrantel pamoate, 11 mg/kg base PO once (max. 1 g), repeat in 2wks Albendazole, 400 mg PO once; repeat in 2wks Botanicals* (see page 7)
Symptoms:
Infection is generally asymptomatic unless there is repeated exposure leading to heavy worm burden. Severe infection can lead to myalgias, abdominal pain, diarrhea, cough, tender liver, ulceration of the intestinal mucosal layer. It has been linked with reactive arthritis and sacroilitis.
Giardia lamblia
Giardia lamblia is a flagellate considered to be a pathogen and the most common cause of diarrheal disease worldwide. Transmitted via contaminated water, food or the fecal-oral route.
Strongyloides sp.
Strongyloides sp. is transmitted via skin contact with contaminated soil, or oral ingestion of the larvae. Larvae are carried to the lungs or are swallowed and mature in the small intestine.
Symptoms:
Often asymptomatic and self-limiting. Symptoms depend on the amount of worms present and the degree of mucosal involvement. Severe infection can result in bloody diarrhea, abdominal pain, nausea and irondeficiency anemia.
Symptoms:
Itching and a rash at the site of penetration. While a light infection may cause no symptoms, heavy infection can cause epigastric pain, nausea and vomiting, gas, and alternating constipation and diarrhea. Has been associated with reactive arthritis.
Treatment Options:
Thiabendazole 50 mg/kg/d in two doses x 2d; Ivermectin 200 mcg/kg/d x 1-2d, or Albendazole 400 mg/d x 3d Eradication is difficult, recheck stool in 3 months Botanicals* (see below)
Treatment Options:
Mebendazole, 100 mg PO bid x 3d or 500 mg once; Albendazole, 400 mg PO x 3d, or Ivermectin, 200 mcg/ kg PO daily x 3d Botanicals* (see below)
Symptoms:
Often asymptomatic. Symptoms include GI complaints such as abdominal pain, anorexia, weight loss or malaise. Vitamin B12 deficiency may result.
Treatment Options:
Praziquantel, 5-10 mg/kg PO once, Niclosamide, 2 g PO once Botanicals* (see below)
Treatment Options:
Address other abnormal results in the GI Effects test first, with the expectation that a rare parasite will be crowded out when healthy conditions are restored. Consider exposures such as pets, sushi, camping, or foreign travel If presentation is consistent with parasite infestation, use a broad spectrum antiparasitic treatment followed by preand probiotics Botanicals* (see below)
*Botanical Treatment
Individualized pharmaceutical interventions are listed below each parasite. Common botanical anti-parasitic herbs for each parasite listed include black walnut, quassia, garlic, berberine, grapefruit seed extract, oil of oregano, barberry, and artemesia. When treating parasites with botanicals, it is recommended to use a blend of several, to lengthen treatment duration, and to rotate antiparasitic agents
Adiposity Index Drug Resistance Genes Short Chain Fatty Acids (SCFA) Adiposity Index
Adiposity Index imbalanced: high firmicutes and low bacteroidetes
Research has indicated that obesity has a microbial component that alters caloric yield from ingested food.[18] Altering the gut microbiota may also improve insulin sensitivity and oral glucose tolerance.[19] Treatments for obesity that result in lowering the percentage of Firmicutes may assist in weight control.
Target Organism:
Gram-positive bacteria, particularly beta-lactamase-producing organisms such as Staphylococcus
gyrB, ParE
Antibiotic
Ciprofloxacin and later generation quinolones
Cause:
Bacteria classes known to increase caloric extraction from food are present Dysbiosis The Firmicutes class consist of Clostridia sp., Streptomyces sp., Lactobacillus sp., Mycoplasma sp., Bacillus sp. (see results under Predominant Bacteria) The Bacteroidetes class consist of Bacteroides sp. and Prevotella sp. (see results under Predominant Bacteria)
Target Organism
Gram-positive and Gram-negative bacteria
PBP1a, PBP2B
Antibiotic:
Penicillin (Beta-Lactam)
Target Organism:
Broad spectrum
Treatment Options:
Balance predominant bacteria using 4R protocol Remove opportunistic bacteria, especially Bacillus sp. Supplement with Bifidobacter sp. and S. boulardii Reduce refined carbohydrates Address all GI Effects imbalances
Treatment Options:
Avoid using class of antibiotics for which patient has drug resistance gene
Cause:
Low anaerobic bacteria (see Predominant Bacteria) Antibiotic treatment Insufficient fiber intake/poor diet Slow transit time (more time for SCFA absorption)
Treatment Options:
Consider pre- and probiotic supplementation if the predominant bacteria are low Psyllium, oat bran, oligofructose, inulin xylooligosaccharide, beta-glucan, or arabinogalactan Increase dietary intake of fruits and vegetables In ulcerative colitis, Crohns or those at risk for colon cancer, consider butyrate enemas or enteric-coated butyrate supplements Enemas are contraindicated for those with GI bleeds
Target Organism:
Gram-positive bacteria (cocci), namely Enterococci
mecA
Antibiotic:
Methicillin (Beta-Lactam)
Target Organism:
Aerobic, Gram-negative
Test Interferences:
Colostrum has a high concentration of lactoferrin, so those breast feeding or supplementing with colostrum could show false positives False negatives can be seen in those with severe immune compromise
Cause:
Bacterial overgrowth[21] Rapid transit time (less time for SCFA absorption)[22] Malabsorption[23] Pancreatic insuffiency resulting in carbohydrate maldigestion and increased bacterial fermentation Bacterial fermentation of blood[24]
Immunology
Depressed Fecal sIgA
Cause:
Chronic stress Immunocompromise Dysbiosis Immuno-suppressing medication
Treatment Options:
Address all GI imbalances including bacterial overgrowth, parasite infection, gluten intolerance, food allergy, vitamin, mineral, or essential fatty acid (EFA) deficiency, or chronic NSAID usage. Normalize transit time Pancreatic enzymes, betaine HCl, or digestive herbs.
Treatment Options:
Support gut mucosa, e.g. glutamine, probiotics (S. boulardii, Bifidobacteria), colostrum, immunoglobulins, essential fatty acids, zinc, and stress reduction Support immune function
Inflammation
Elevated Lactoferrin, WBCs, or Mucus present
Lactoferrin is an iron-binding glycoprotein released from neutrophils during inflammation. It is a marker of leukocyte activity and is a primary component of the hosts first line immune defense against infection.
Cause:
Mucosal inflammation Bacterial or yeast overgrowth Parasite infection Inflammatory bowel disease, e.g. Crohns, ulcerative colitis
Treatment Options:
Support immune function Remove pathogens, parasites, opportunistic bacteria, virus Rule out food sensitivities Elimination diet
Treatment Options:
Due to infection: Remove pathogens Probiotics and prebiotics to replenish beneficial bacteria and establish proper balance Enhance the endogenous immune (sIgA) defense by supplementing with L-glutamine, S. boulardii and/or colostrum Due to non-infectious inflammation, e.g. Inflammatory Bowel Disease: Balance the intestinal flora, if indicated Anti-inflammatory herbs and nutrients, e.g. turmeric, ginger, EPA/DHA, quercetin, antioxidants
Treatment Options:
Remove gluten on trial basis Consider Celiac Profile Consider nutrients and herbs for mucosal healing Additional Tests
Positive RBCs
Cause:
Bleeding in lower GI from hemorrhoids, intestinal polyps, or tears around the anus due to constipation Those with compromised liver function are more likely to develop hemorrhoids
Treatment Options:
Treat constipation if present Consider colonoscopy to identify source, treat accordingly Assess liver function Soothe and repair gut mucosa RBCs, occult blood
Treatment Options:
Support digestion and absorption Supplementary plant or pancreatic enzymes, betaine HCl, disaccharidases (if needed) Normalize transit time Address all GI Effects imbalances
Digestion
Depressed Elastase 1
Elastase 1 is a digestive enzyme excreted by the pancreas, exclusively, and has a direct correlation with pancreatic function. Elastase 1 results are not affected by pancreatic enzyme replacement therapy.[27,28] Optimal levels are > 500.
Elevated pH
Cause:
Decreased bacterial production of SCFAs Insufficient flora, dietary fiber, or water Inadequate acid-producing organisms such as Lactobacillus sp. Hypochlorhydria A high meat diet can stimulate ammonia production in the bowel Slow transit time (more time for SCFA absorption) Elevated pH increases risk for colon cancer
Cause:
Suppressed pancreatic function Gallstones or post-cholecystectomy Chronic pancreatitis Diabetes Hypochlorhydria Cystic fibrosis
Treatment Options:
Supplement with probiotics Increase dietary fiber (esp. soluble) and water to increase SCFA production and normalize transit time Support digestion Supplementation with betaine HCl or herbs to stimulate gastric acid production, including ginger, peppermint, etc. Address all GI Effects imbalances
Treatment Options:
Support digestion with betaine HCl with pepsin, or plant or pancreatic enzymes or digestive herbs Bile salts, taurine, or cholagogues (esp. if high triglycerides and constipation) Relax while eating and chew thoroughly Support diabetes regulation
Treatment Options:
Repeat occult blood test on two more occasions Address all GI Effects imbalances Rule out iron deficiency anemia Consider sigmoidoscopy or colonoscopy to identify source, treat accordingly Anti-inflammatory medical food Anti-inflammatory diet Food allergens
Treatment Options:
Support digestion with betaine HCl with pepsin, plant or pancreatic enzymes or digestive herbs Bile salts, taurine, or cholagogues (esp. if high triglycerides and constipation) Relax while eating and chew thoroughly
10
Digestion Absorption
Elevated Putrefactive SCFA
Cause:
Protein maldigestion Hypochlorhydria Pancreatic insufficiency Malabsorption, esp. if elevated long chain fatty acids or cholesterol Bacterial overgrowth of the small intestine
Treatment Options:
Support digestion with betaine HCl with pepsin, plant or pancreatic enzymes or digestive herbs Treat any underlying pancreatitis Consider nutrients and herbs for mucosal support: L-glutamine, Zn, EFAs, Vitamins A, E, and C, pantothenic acid, N-acetyl glucosamine, glycyrrhiza, aloe vera, slippery elm, etc. Eliminate infection, address gluten intolerance, and food sensitivities
Absorption
Elevated LCFA, Total Fat, or Cholesterol
Cause:
Malabsorption due to diarrhea, intestinal dysbiosis, parasites, colitis, gluten intolerance, food allergy, essential fatty acid deficiency, pancreatic or bile salt insufficiency and/or chronic NSAID usage [29] High dietary fat intake Medications designed to bind and eliminate fats If elevated cholesterol, suspect malabsorption, high dietary intake or increased mucosal cell turnover resulting from inflammation [30, 31] Bacterial overgrowth of the small intestine (esp. if elevated SCFAs) Bacterial enzymes can also impair micelle formation, resulting in lipid malabsorption
Treatment Options:
Support digestion with supplementary plant or pancreatic enzymes, betaine HCl, digestive herbs, bile salts or cholagogues, taurine or glycine, if indicated Address food sensitivities or gluten intolerance Check vitamin (esp. fat-soluble), mineral, and EFA status Support mucosal health with nutrients such as L-glutamine, Zn, EFAs, Vitamins A, E, and C, pantothenic acid, N-acetyl glucosamine, glycyrrhiza, aloe vera, slippery elm, etc. Address all GI Effects imbalances
11
Botanical
Wormwood (Artemesia) Olive leaf Uva Ursi (Bearberry) Garlic Undecylenic acid (from castor bean) Oil of thyme Oil of oregano Goldenseal Cats Claw Black Walnut
Active ingredient
Artemisinin Oleuropein Arbutin Alliin Undecylenic acid Thymol Carvacrol Berberine Quinic acid 5-hydroxy-1,4-naphthoquinone
References
1. 2. 3. 4. Guarner, F. and J.R. Malagelada, Gut flora in health and disease. Lancet, 2003. 361(9356): p. 512-9. C., S., A dynamic partnership: Celebrating our gut flora. Anaerobe, 2005. 11(5): p. 247-251. Lorian, V., Colonization resistance. Antimicrob Agents Chemother, 1994. 38(7): p. 1693. Wang, M., et al., Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. FEMS Microbiol Ecol, 2005. 54(2): p. 219-31. Camilleri, M., Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol, 2006. 40(3): p. 264-9. Gibson, G.R., Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutr, 1999. 129(7 Suppl): p. 1438S-41S. Endresen, G.K., Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. Rheumatol Int, 2003. 23(5): p. 211-5. Coronado, B.E., S.M. Opal, and D.C. Yoburn, Antibiotic-induced D-lactic acidosis. Ann Intern Med, 1995. 122(11): p. 839-42. Parracho, H.M., et al., Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol, 2005. 54(Pt 10): p. 987-91. Finegold, S.M., Therapy and epidemiology of autism--clostridial spores as key elements. Med Hypotheses, 2008. 70(3): p. 508-11. Tomazinho, L.F. and M.J. Avila-Campos, Detection of Porphyromonas gingivalis, Porphyromonas endodontalis, Prevotella intermedia, and Prevotella nigrescens in chronic endodontic infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007. 103(2): p. 285-8. de Bortoli, N., et al., Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol, 2007. 102(5): p. 951-6. Jarosz, M., et al., Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Eur J Cancer Prev, 1998. 7(6): p. 449-54. Drugs for Parasite Infections. In: Treatments Guidelines from the Medical Letter, 2007. Vol 5 (suppl). Noel, C., et al., Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. J Clin Microbiol, 2005. 43(1): p. 348-55. Puthia, M.K., et al., Blastocystis ratti induces contact-independent apoptosis, F-actin rearrangement, and barrier function disruption in IEC-6 cells. Infect Immun, 2006. 74(7): p. 4114-23.
5.
23. 24.
6. 7. 8. 9.
25.
10. 11.
12.
Kaneda, Y., et al., Ribodemes of Blastocystis hominis isolated in Japan. Am J Trop Med Hyg, 2001. 65(4): p. 393-6. Ley, R.E., et al., Microbial ecology: human gut microbes associated with obesity. Nature, 2006. 444(7122): p. 1022-3. Membrez, M., et al., Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. Faseb J, 2008. Royall, D., T.M. Wolever, and K.N. Jeejeebhoy, Clinical significance of colonic fermentation. Am J Gastroenterol, 1990. 85(10): p. 1307-12. Hoverstad, T., et al., Short-chain fatty acids in the small-bowel bacterial overgrowth syndrome. Scand J Gastroenterol, 1985. 20(4): p. 492-9. Oufir, L.E., et al., Relationships between transit time in man and in vitro fermentation of dietary fiber by fecal bacteria. Eur J Clin Nutr, 2000. 54(8): p. 603-9. Scheppach, W., et al., The effect of starch malabsorption on fecal short-chain fatty acid excretion in man. Scand J Gastroenterol, 1988. 23(6): p. 755-9. Holtug, K., H.S. Rasmussen, and P.B. Mortensen, Short chain fatty acids in inflammatory bowel disease. The effect of bacterial fermentation of blood. Scand J Clin Lab Invest, 1988. 48(7): p. 667-71. Howarth, G.F., et al., High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial. Am J Gastroenterol, 2002. 97(3): p. 690-4. Kronborg, O., Diverticulitis: a new high-risk group for colorectal cancer? Scand J Gastroenterol, 2004. 39(8): p. 707-8. Lser Chr, Mllgard A, Flsch UR. Faecal elastase1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996; 39: 580-586. Stein J, Jung M, Sziegoleit A, Zeuzem S, Caspary WF, Lembcke B. Immunoreactive elastase1: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem. 1996; 42:222-226. Brody, T., Nutritional Biochemistry. 2nd. ed. 1999, San Diego: Academic Press. xix, 1006 p. Thomson, A.B.R., First Principles of Gastroenterology: The Basis of Disease and an Approach to Management. 2000: Gastroenterology Resource Centre. Vuoristo, M. and T.A. Miettinen, Increased biliary lipid secretion in celiac disease. Gastroenterology, 1985. 88(1 Pt 1): p. 134-42.
13.
14. 15.
16
12